Video

Role of Immunotherapy in Early Stage NSCLC Treatment

Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.

John V. Heymach, MD, PhD: There’s been an important development in the field. We’ve just spent this whole session talking about metastatic disease, but for early stage disease, on the order of half the patients still recur, and there are no approved immunotherapy agents in the neoadjuvant or adjuvant setting. Heather, do you want to briefly tell us about the IMpower110 results and the results of that exciting study?

Heather Wakelee, MD: Sure, absolutely. We initially presented the data at ASCO [American Society of Clinical Oncology Annual Meeting], so this was a randomized phase 3 global trial looking at adjuvant atezolizumab for patients who had had complete surgical resection and then had chemotherapy, so chemotherapy was a mandated part of the study. We had a complicated statistical analysis plan, but the first group was stage II/IIIA, who had PD-L1 expression of at least 1%. The hazard ratio there was 0.66 for disease-free survival [DFS]. When we took out those with PD-L1 expression, the hazard ratio shrunk, still statistically significant, but…the benefit is all in patients who have PD-L1 expression. Also, in that subgroup, the atezolizumab is quite effective, especially in those with greater than 50% expression.

We’re still doing analysis. When we bring in all comers, which includes the 12% of patients who have stage IB disease, we haven’t had enough events to say 1 way or the other statistically and haven’t had enough events for overall survival. We had some updates at World Conference on Lung Cancer looking at the chemotherapy regimens and surgical outcomes and then at ESMO [European Society for Medical Oncology Congress] looking at some of the other PD-L1 expression that just got published in The Lancet. This was a strong DFS benefit. With immunotherapy, I’m very hopeful that that’s going to translate into overall survival benefit. We also know that there are many other adjuvant I/O [immuno-oncology] trials that we’re going to be hearing about shortly. We haven’t yet, so we’ll see how that fits together.

John V. Heymach, MD, PhD: Stay tuned because it looks unquestionable that immunotherapy will be part of how we treat early stage patients. I’m looking forward to how this plays out.

Transcript Edited for Clarity

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
Hidehito Horinouchi, MD, PhD